We previously reported the in vivo expansion and robust antileukemic effects of CTL019 (formerly CART19) cells in three patients with CLL. 7,8 CTL019 is a chimeric antigen receptor that includes a ...

After infusion, CAR T cells leave the blood and travel to sites of tumor, where they identify and kill tumor cells. This can trigger extensive proliferation of CAR T cells and the release of tumor ...

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by ...

Current clinical outcomes using chimeric-antigen receptors (CARs) against multiple myeloma show promise in the eradication of bulk disease. However, these anti-BCMA (CD269) CARs observe relapse as ...

Serum perforin decreased after chemotherapy administration. Fig 2. Chimeric antigen receptor (CAR) targeting CD19 (CAR-19) T cells eradicated large masses of chemotherapy-refractory lymphoma. (A) ...

Jensen et al 17 showed that outcomes of 15 CD19- or CD20-specific chimeric antigen receptor T-cell (CAR-T) infusions in 4 patients were limited by short persistence of 1-7 days, attributed to ...

Adoptive T cell therapy using Chimeric Antigen Receptor T cells (CAR T) has made significant advances in the treatment of hematologic malignancies and solid tumors. However, a key challenge remains ...

(1) A chimeric antigen receptor (CAR) is a modular, synthetic receptor that endows T cells with different targeting abilities. Several emerging engineering approaches aim to improve the safety, ...

This is best exemplified by chimeric antigen receptor (CAR) T-cells. Since first being tested in a patient nearly 15 years ago, six CAR T-cell products have been approved by the US Food and Drug ...

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...